Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 3
1996 2
1997 1
1998 4
2000 3
2001 3
2002 4
2003 13
2004 16
2005 13
2006 41
2007 29
2008 57
2009 71
2010 90
2011 85
2012 110
2013 114
2014 121
2015 145
2016 182
2017 144
2018 132
2019 119
2020 135
2021 167
2022 132
2023 101
2024 46

Text availability

Article attribute

Article type

Publication date

Search Results

1,850 results

Results by year

Filters applied: . Clear all
Page 1
Ivabradine and endothelium: an update.
Dallapellegrina L, Sciatti E, Vizzardi E. Dallapellegrina L, et al. Ther Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720934937. doi: 10.1177/1753944720934937. Ther Adv Cardiovasc Dis. 2020. PMID: 32611276 Free PMC article. Review.
Moreover, interesting effect of ivabradine on endothelial and myocardial function and on oxidative stress and inflamation pathways are progressively emerging. The aim of this paper is to highlight newer evidences about ivabradine effect (and consequently possible fu …
Moreover, interesting effect of ivabradine on endothelial and myocardial function and on oxidative stress and inflamation pathways ar …
Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome.
Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Taub PR, et al. J Am Coll Cardiol. 2021 Feb 23;77(7):861-871. doi: 10.1016/j.jacc.2020.12.029. J Am Coll Cardiol. 2021. PMID: 33602468 Free article. Clinical Trial.
METHODS: In total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized, double-blinded, placebo-controlled, crossover trial with ivabradine. Patients were randomized to start either ivabradine or placebo for 1 month, and then were …
METHODS: In total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized, double-blinded, placebo-controll …
Ivabradine for the Treatment of Cardiovascular Diseases.
Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ide T, et al. Circ J. 2019 Jan 25;83(2):252-260. doi: 10.1253/circj.CJ-18-1184. Epub 2018 Dec 29. Circ J. 2019. PMID: 30606942 Free article. Review.
The hyperpolarization-activated cyclic nucleotide-gated (HCN) 4 channel, one of 4 HCN isoforms, generates the I(f) current and plays an important role in the regulation of pacemaker activity in the sinoatrial node. Ivabradine is a novel and only available HCN inhibitor, wh …
The hyperpolarization-activated cyclic nucleotide-gated (HCN) 4 channel, one of 4 HCN isoforms, generates the I(f) current and plays an impo …
Ivabradine for treatment of heart failure.
Bocchi EA, Salemi VMC. Bocchi EA, et al. Expert Opin Drug Saf. 2019 May;18(5):393-402. doi: 10.1080/14740338.2019.1612873. Epub 2019 May 10. Expert Opin Drug Saf. 2019. PMID: 31074301 Review.
In chagasic patients, ivabradine reduced HR and a trend toward reduction in all-cause death was observed with ivabradine (p = 0.07). In children with HFrEF, ivabradine increased NYHA functional class. The most common side effects with ivabradine are br …
In chagasic patients, ivabradine reduced HR and a trend toward reduction in all-cause death was observed with ivabradine (p = …
Ivabradine in Cardiovascular Disease Management Revisited: a Review.
Chen C, Kaur G, Mehta PK, Morrone D, Godoy LC, Bangalore S, Sidhu MS. Chen C, et al. Cardiovasc Drugs Ther. 2021 Oct;35(5):1045-1056. doi: 10.1007/s10557-020-07124-4. Epub 2021 Jan 7. Cardiovasc Drugs Ther. 2021. PMID: 33411112 Review.
Ivabradine is a unique agent that is distinct from beta-blockers and calcium channel blockers as it reduces heart rate without affecting myocardial contractility or vascular tone. Ivabradine is a use-dependent inhibitor targeting the sinoatrial node. ...
Ivabradine is a unique agent that is distinct from beta-blockers and calcium channel blockers as it reduces heart rate without affect …
Ivabradine for controlling heart rate in permanent atrial fibrillation: A translational clinical trial.
Fontenla A, Tamargo J, Salgado R, López-Gil M, Mejía E, Matía R, Toquero J, Montilla I, Rajjoub EA, García-Fernandez FJ, Miracle A, Rey JR, Bueno H; BRAKE-AF Study Investigators. Fontenla A, et al. Heart Rhythm. 2023 Jun;20(6):822-830. doi: 10.1016/j.hrthm.2023.02.012. Heart Rhythm. 2023. PMID: 37245897 Clinical Trial.

Thirty-five (51.5%) patients were randomized to ivabradine and 33 (49.5%) to digoxin. The mean daytime heart rate decreased by 11.6 beats/min (-11.5%) in the ivabradine arm (P = .02) vs 19.6 (-20.6%) in the digoxin arm (P < .001), although the noninferiority marg

…
Thirty-five (51.5%) patients were randomized to ivabradine and 33 (49.5%) to digoxin. The mean daytime heart rate decreased by 11.6 b …
Effect of ivabradine on cardiac arrhythmias: Antiarrhythmic or proarrhythmic?
Marciszek M, Paterek A, Oknińska M, Zambrowska Z, Mackiewicz U, Mączewski M. Marciszek M, et al. Heart Rhythm. 2021 Jul;18(7):1230-1238. doi: 10.1016/j.hrthm.2021.03.020. Epub 2021 Mar 15. Heart Rhythm. 2021. PMID: 33737235 Review.
Therefore, implantable devices remain the only truly effective antiarrhythmic therapy, and new strategies of antiarrhythmic treatment are required. Ivabradine is a selective heart rate-reducing agent, an inhibitor of hyperpolarization-activated, cyclic nucleotide-gated (HC …
Therefore, implantable devices remain the only truly effective antiarrhythmic therapy, and new strategies of antiarrhythmic treatment are re …
Optimal Heart Rate Modulation Using Ivabradine.
Imamura T, Kinugawa K. Imamura T, et al. Int Heart J. 2021 Jul 30;62(4):717-721. doi: 10.1536/ihj.21-355. Epub 2021 Jul 17. Int Heart J. 2021. PMID: 34276025 Free article. Review.
Heart rate modulation therapy using ivabradine improves mortality and morbidity in patients with systolic dysfunction. However, a target heart rate remains uncertain. Echocardiography-guided ivabradine therapy, in which we attempt to approach zero overlap between tw …
Heart rate modulation therapy using ivabradine improves mortality and morbidity in patients with systolic dysfunction. However, a tar …
Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering.
Niccoli G, Borovac JA, Vetrugno V, Camici PG, Crea F. Niccoli G, et al. Int J Cardiol. 2017 Jun 1;236:107-112. doi: 10.1016/j.ijcard.2017.02.046. Epub 2017 Feb 22. Int J Cardiol. 2017. PMID: 28256323 Review.
However, the role of Ivabradine in acute coronary syndromes has not been established. Based on the results from some relevant preclinical studies and a limited amount of clinical data that were reported recently, the role of Ivabradine in acute ischemic events warra …
However, the role of Ivabradine in acute coronary syndromes has not been established. Based on the results from some relevant preclin …
Ivabradine for Postoperative JET: Clear for Take-Off?
Janson CM, Clancy CE. Janson CM, et al. JACC Clin Electrophysiol. 2021 Aug;7(8):1061-1063. doi: 10.1016/j.jacep.2021.03.015. JACC Clin Electrophysiol. 2021. PMID: 34412869 Free article. No abstract available.
1,850 results